title: [Viral hepatitis infection and response to the hepatitis B vaccine in hemodialyzed patients].
abstract: Data from 219 hemodyalized patients receiving attention in our Hospital and other private centers in our city are shown. Mean age was 46.9 (range: 14-85), and 132 were male; mean time under dialysis was 20 months, and subjects received an average of 5 transfusions per patient year. Serological reactivity to HBs Ag, Anti HBs and IgG anti HBc by ELISA were investigated in all of them, and anti HCV by second generation enzimo-immunoassay (EIA II) in 73 HBe Ag/anti HBe system were determined in HBs Ag positive patients and those reactive to anti HCV (EIA II) were confirmed by LIA (immunoblotting of synthetic peptides LIA-TEK Organos Teknica). Recombinant anti HBV vaccine 40 mcg at 0-1 and six month were received by 81 cases without HBV markers in their sera and a protective response was considered when anti HBs titration of 10 mU/ml or more were obtained two months later. Prevalence for anti HBc and anti HBs were 38.8% respectively and that for HBs Ag was 21% with 78% of them reactive for HBs Ag. True reactivity for anti HCV (confirmed by LIA) was present in 35.6%, but it was 9.7% in our Hospital and 54.8% in private units (p < 0.0002). Anti HBs titration was done in 69/81 patients who received anti HBV vaccine, and a protective response in 49% were obtained; the other 12 patients underwent acute hepatitis B during the vaccination period.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: HIGA, General San Martín de La Plata, Servicio de Gastroenterología, Argentina.
authors.forename: J O
authors.initials: JO
authors.lastname: Curciarello
authors.forename: O
authors.initials: O
authors.lastname: Corallini
authors.forename: R E
authors.initials: RE
authors.lastname: Adrover
authors.forename: A O
authors.initials: AO
authors.lastname: Chiera
authors.forename: A M
authors.initials: AM
authors.lastname: Giammona
authors.forename: R
authors.initials: R
authors.lastname: Barbero
authors.forename: M
authors.initials: M
authors.lastname: Apraiz
authors.forename: P O
authors.initials: PO
authors.lastname: Belloni
authors.forename: M
authors.initials: M
authors.lastname: Neumann
authors.forename: A C
authors.initials: AC
authors.lastname: Jmelnitzky
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000097:blood; D006511:Hepatitis B Antigens / Q000097:blood; D017325:Hepatitis B Vaccines; D006526:Hepatitis C / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects*; D065227:Transfusion Reaction
chemical_list: D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D017325:Hepatitis B Vaccines
vernacular_title: Infección por virus de hepatitis y respuesta a vacuna anti-hepatitis B en hemodializados.